Rare non-small cell lung cancer with brain metastases responds to amivantamab monotherapy
A team led by first author Jinah Kim of the University of Vermont Medical Center and corresponding author Young Kwang Chae of Feinberg School of Medicine reports on a clinical case in which a patient with advanced non-small cell lung cancer (NSCLC) and rare EGFR mutations responded remarkably well to amivantamab after other treatments had failed. The patient experienced complete resolution of brain and cerebrospinal fluid metastases. This suggests that amivantamab could be a viable option for patients with unusual genetic profiles and limited treatment options. Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Patients with NSCLC and rare mutations in the EGFR gene often have limited treatment options and poor prognoses, especially if the disease has spread to the brain or cerebrospinal fluid. This case involved a 67-year-old man diagnosed with NSCLC who had two rare EGFR mutations – G719A…



